NCT00790673View on ClinicalTrials.gov

A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

July 31, 2011

Conditions

Chronic Hepatitis C

Interventions

DRUG

CF 102

Oral capsules

DRUG

Placebo

Matching placebo capsules

Trial Locations (1)

Unknown

Rabin Medical Center, Tel Aviv

Sponsors

Lead Sponsor

Can-Fite BioPharma

All Listed Sponsors

lead

Can-Fite BioPharma

INDUSTRY